Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > TLT 2022

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Mar 04, 2021 2:19pm

201 Views

Post# 32716929

RE:TLT 2022

Yes and TLT's IP is worth more IMO, especially to Merck. They'd be smart to buy TLT to protect their Keytruda product.

Mikee3003 wrote: Our turn coming.....

12:44 PM EST, 03/04/2021 (MT Newswires) -- Amgen (AMGN) entered a $1.9-billion acquisition deal with Five Prime Therapeutics (FPRX) to strengthen its oncology portfolio and support its strategic global expansion, according to the companies' joint statement on Thursday.
Thousand Oaks, California-based Amgen will acquire Five Prime at $38 per share, a premium to the biotechnology company's closing price of $21.26 on Wednesday. The shares of South San Francisco, California-based Five Prime surged 78% on Thursday afternoon.

The deal includes Five Prime's bemarituzumab, a targeted antibody being developed for the treatment of gastric cancer. Amgen plans to expand its presence in the Asia-Pacific region, particularly in Japan, to boost the potential of the therapy.